High throughput genetics to enhance long-term efficacy and function of CAR-T cell therapy in solid cancers

高通量遗传学可增强 CAR-T 细胞疗法在实体癌中的长期疗效和功能

• 批准号: 2895113
• 金额: --
• 依托单位: University of Cambridge
• 依托单位国家: 英国
• 项目类别: Studentship
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=studentship-2895113
• 关键词: throughput; genetics; enhance; long; term

Chimeric antigen receptor (CAR) T cell therapy involves genetically engineering T cells to express CAR which redirect their specificity to target tumour-expressed antigens. While CAR-T cell therapies have led to remarkable clinical responses in haematological malignancies the response in solid cancers has so far been limited. The aim of this project is to use high-throughput functional screens to identify genetic means of improving solid cancer CAR-T cell efficacy by (a) preventing CAR-T dysfunction and (b) armouring CAR-T cells to overcome immune suppression within the solid tumour microenvironment.

嵌合抗原受体(CAR)T细胞治疗包括对表达CAR的T细胞进行基因工程，从而将其特异性重定向到肿瘤表达的靶抗原。虽然CAR-T细胞疗法在血液系统恶性肿瘤中取得了显着的临床反应，但对实体肿瘤的反应到目前为止还很有限。该项目的目的是使用高通量功能筛选来确定通过(A)预防CAR-T功能障碍和(B)装甲CAR-T细胞以克服固体肿瘤微环境中的免疫抑制来提高实体癌CAR-T细胞有效性的遗传方法。